# Tim A. Kanters

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tim-a-kanters/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,078 |
| Field | Health Systems, Economic Evaluations, Quality of Life |
| h-index | 21 |
| i10-index | 29 |
| Last Known Institution | Erasmus University Rotterdam |
| OpenAlex ID | https://openalex.org/A5004336116 |
| ORCID iD | 0000-0003-0129-7961 |
| Works | 63 |

## Researcher papers

- [Update of the Dutch manual for costing studies in health care](https://scholariq.org/papers/update-of-the-dutch-manual-for-costing-studies-in-health-care/)
- [Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow‐up](https://scholariq.org/papers/quality-of-life-and-participation-in-daily-life-of-adults-with-pompe-disease/)
- [Burden of illness of Pompe disease in patients only receiving supportive care](https://scholariq.org/papers/burden-of-illness-of-pompe-disease-in-patients-only-receiving-supportive-care/)
- [Potential cost savings owing to the route of administration of oncology drugs](https://scholariq.org/papers/potential-cost-savings-owing-to-the-route-of-administration-of-oncology-drugs/)
- [Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease](https://scholariq.org/papers/cost-effectiveness-of-enzyme-replacement-therapy-with-alglucosidase-alfa-in/)
- [Burden of illness of hip fractures in elderly Dutch patients](https://scholariq.org/papers/burden-of-illness-of-hip-fractures-in-elderly-dutch-patients/)
- [Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria](https://scholariq.org/papers/cost-effectiveness-of-omalizumab-for-the-treatment-of-chronic-spontaneous/)
- [Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic](https://scholariq.org/papers/productivity-of-working-at-home-and-time-allocation-between-paid-work-unpaid/)
- [Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel](https://scholariq.org/papers/adoption-of-biosimilar-infliximab-for-rheumatoid-arthritis-ankylosing/)
- [The impact of informal care for patients with Pompe disease: An application of the CarerQol instrument](https://scholariq.org/papers/the-impact-of-informal-care-for-patients-with-pompe-disease-an-application-of/)
- [Caregiver Burden and Quality of Life Across Alzheimer’s Disease Severity Stages](https://scholariq.org/papers/caregiver-burden-and-quality-of-life-across-alzheimer-s-disease-severity-stages/)

## Researcher topics

- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Lysosomal Storage Disorders Research](https://scholariq.org/topics/lysosomal-storage-disorders-research/)
- [Glycogen Storage Diseases and Myoclonus](https://scholariq.org/topics/glycogen-storage-diseases-and-myoclonus/)
- [Pharmaceutical studies and practices](https://scholariq.org/topics/pharmaceutical-studies-and-practices/)
- [Whipple's Disease and Interleukins](https://scholariq.org/topics/whipple-s-disease-and-interleukins/)

## Researcher university

- [Erasmus University Rotterdam](https://scholariq.org/institutions/erasmus-university-rotterdam/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.